Crohn's disease future or investigational therapies

Jump to: navigation, search

Crohn's disease

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Crohn's Disease from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Crohn's disease future or investigational therapies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Crohn's disease future or investigational therapies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Crohn's disease future or investigational therapies

CDC on Crohn's disease future or investigational therapies

Crohn's disease future or investigational therapies in the news

Blogs on Crohn's disease future or investigational therapies

Directions to Hospitals Treating Crohn's disease

Risk calculators and risk factors for Crohn's disease future or investigational therapies

Ustekinumab

Recent studies have found that in patients refarctory to treatment with tumor necrosis factor (TNF) antagonists, subcutaneously administered maintenance doses of ustekinumab showed a significant benefit in terms of clinical response but not remission, and were efficacious during a period of 22 weeks.[1]

References



Linked-in.jpg